Xinjiang Clinical Trials Face Ethical Questions: Can 'Informed Consent' Stand Up to Scrutiny in a High-Pressure Environment?

Xinjiang Clinical Trials Face Ethical Questions: Can 'Informed Consent' Stand Up to Scrutiny in a High-Pressure Environment?

The Congressional-Executive Commission on China (CECC) has stated that multiple international pharmaceutical companies have conducted clinical trials in Xinjiang hospitals. Although there is currently no evidence of illegality, the background of large-scale surveillance and forced medical checks in the region has raised new ethical concerns about whether participants can truly give informed consent.

Clinical trials of international drugs conducted in Xinjiang are under new ethical scrutiny. The CECC released a report titled "China Outlook" on August 20, stating that several US and international pharmaceutical companies have conducted clinical trials in Xinjiang hospitals over the years. The region has long been plagued by large-scale surveillance, forced medical checks, and forced labor, which raises questions about whether participants can truly refuse to participate.

According to publicly available information cited by the CECC, between 2010 and 2025, US companies with a large number of clinical trials in Xinjiang included Merck, AbbVie, Eli Lilly, Bristol Myers Squibb, and Amgen, as well as international pharmaceutical companies such as AstraZeneca, Novartis, Roche, and Bayer.

Figure: A page from the 7th issue of the CECC's "China Outlook" related to the topic of clinical trials in Xinjiang.

In June, US lawmakers sent letters to several pharmaceutical companies, asking them to explain how they ensured that participants in Xinjiang were not coerced into participating in trials and how they handled potential data and ethical risks associated with conducting research in People's Liberation Army hospitals. The CECC emphasized that there is currently no evidence to prove that these companies have engaged in illegal activities.

This distinction is crucial. Whether a clinical trial is illegal depends on the specific research plan, ethical review, informed consent records, and local laws. However, the absence of evidence of illegality does not mean that ethical concerns do not exist. International medical ethics typically require that participants be able to refuse to participate without penalty or pressure and fully understand the risks associated with the research.

Xinjiang's unique situation lies in the fact that over the past decade, the region's state surveillance, forced physical examinations, biometric data collection, and large-scale detentions have been documented by multiple international organizations. In such an environment, even if the informed consent form is formally complete, it is still necessary to question whether participants believe they have the right to refuse and whether refusal would affect their work, welfare, or relationship with the government.

The CECC also pointed out that Pfizer has decided not to conduct clinical trials in Xinjiang and Chinese military hospitals. This indicates that companies are reevaluating their compliance and reputational risks. For other multinational pharmaceutical companies, the key in the future may not only be "can we do it" but also whether they can prove that every participant is participating under truly voluntary conditions.